Polymeric nanoparticles (NPs) represent one of the most studied carriers for drug delivery, due to their ability in overcoming problems related to the instability of drugs and their widespread biodistribution as well as for the possibility of targeting cells or organs [1]. In particular, drug delivery to the brain is a challenge for scientists, since the Blood Brain Barrier (BBB) allows the entrance of specific and selected molecules, but it hampers the passage of a remarkable number of pharmacologically active molecules. A plethora of strategies aims to create, characterize and test in vitro and in vivo NPs able to cross the BBB, in health or diseased state, i.e. with physiological or enhanced permeability [2]. Nearly all the strategies involved are based on moieties, as surfactants, antibodies, ligands for receptors and peptides [3-7] linked on the NPs surface (engineered NPs). Beside the “BBB crossing aim”, NPs targeted to the Central Nervous System (CNS) have to be planned considering their “journey into the body” [8], as the biodistribution of the nanocarriers and the route of administration is another aspect to be taken into account.

Brain targeting with polymeric nanoparticles: which administration route should we take? / Tosi, Giovanni; Ruozi, Barbara; Vandelli, Maria Angela. - In: NANOMEDICINE. - ISSN 1748-6963. - STAMPA. - 8:9(2013), pp. 1361-1363. [10.2217/NNM.13.135]

Brain targeting with polymeric nanoparticles: which administration route should we take?

TOSI, Giovanni;RUOZI, Barbara;VANDELLI, Maria Angela
2013

Abstract

Polymeric nanoparticles (NPs) represent one of the most studied carriers for drug delivery, due to their ability in overcoming problems related to the instability of drugs and their widespread biodistribution as well as for the possibility of targeting cells or organs [1]. In particular, drug delivery to the brain is a challenge for scientists, since the Blood Brain Barrier (BBB) allows the entrance of specific and selected molecules, but it hampers the passage of a remarkable number of pharmacologically active molecules. A plethora of strategies aims to create, characterize and test in vitro and in vivo NPs able to cross the BBB, in health or diseased state, i.e. with physiological or enhanced permeability [2]. Nearly all the strategies involved are based on moieties, as surfactants, antibodies, ligands for receptors and peptides [3-7] linked on the NPs surface (engineered NPs). Beside the “BBB crossing aim”, NPs targeted to the Central Nervous System (CNS) have to be planned considering their “journey into the body” [8], as the biodistribution of the nanocarriers and the route of administration is another aspect to be taken into account.
8
9
1361
1363
Brain targeting with polymeric nanoparticles: which administration route should we take? / Tosi, Giovanni; Ruozi, Barbara; Vandelli, Maria Angela. - In: NANOMEDICINE. - ISSN 1748-6963. - STAMPA. - 8:9(2013), pp. 1361-1363. [10.2217/NNM.13.135]
Tosi, Giovanni; Ruozi, Barbara; Vandelli, Maria Angela
File in questo prodotto:
File Dimensione Formato  
Editorial 2013.pdf

non disponibili

Tipologia: Post-print dell'autore (bozza post referaggio)
Dimensione 534.66 kB
Formato Adobe PDF
534.66 kB Adobe PDF   Visualizza/Apri   Richiedi una copia
Pubblicazioni consigliate

Caricamento pubblicazioni consigliate

Licenza Creative Commons
I metadati presenti in IRIS UNIMORE sono rilasciati con licenza Creative Commons CC0 1.0 Universal, mentre i file delle pubblicazioni sono rilasciati con licenza Attribuzione 4.0 Internazionale (CC BY 4.0), salvo diversa indicazione.
In caso di violazione di copyright, contattare Supporto Iris

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11380/963496
Citazioni
  • ???jsp.display-item.citation.pmc??? 0
  • Scopus 6
  • ???jsp.display-item.citation.isi??? 6
social impact